Sartorius Stedim Biotech (OTCMKTS:SDMHF) Stock Price Down 1.6% – Here’s What Happened

Sartorius Stedim Biotech S.A. (OTCMKTS:SDMHF)’s stock price dropped 1.6% during trading on Monday . The stock traded as low as $178.3001 and last traded at $178.3001. Approximately 2,900 shares changed hands during mid-day trading, an increase of 16% from the average daily volume of 2,496 shares. The stock had previously closed at $181.29.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on SDMHF shares. The Goldman Sachs Group lowered Sartorius Stedim Biotech from a “buy” rating to a “neutral” rating in a research note on Monday, January 12th. Barclays reaffirmed an “overweight” rating on shares of Sartorius Stedim Biotech in a research note on Tuesday, January 6th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Sartorius Stedim Biotech presently has a consensus rating of “Hold”.

Sartorius Stedim Biotech Stock Down 1.6%

The firm’s 50 day moving average price is $222.24 and its two-hundred day moving average price is $225.80.

About Sartorius Stedim Biotech

Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.

Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems.